Home
STRO
STRO News

Latest Sutro Biopharma Inc. (STRO) News on September 10, 2025

Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?

Zacks

3 months ago

Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?

MT Newswires

3 months ago

Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

GlobeNewswire

3 months ago

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

4 months ago

Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

4 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

GlobeNewswire

4 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

TipRanks

6 months ago

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

MT Newswires

6 months ago

HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2

MT Newswires

6 months ago

Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform

MT Newswires

6 months ago

Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

GlobeNewswire

6 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls

TipRanks

6 months ago

Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

TipRanks

6 months ago

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

GuruFocus.com

6 months ago

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

6 months ago

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8

MT Newswires

6 months ago

Sector Update: Health Care Stocks Higher Premarket Friday

MT Newswires

6 months ago

Sector Update: Health Care

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

GuruFocus.com

6 months ago

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

MT Newswires

6 months ago

Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8

MT Newswires

6 months ago

Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating

MT Newswires

6 months ago

Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

GlobeNewswire

6 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

GlobeNewswire

6 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Zacks

6 months ago

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

6 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Simply Wall St.

8 months ago

We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

8 months ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

GlobeNewswire

8 months ago

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.

9 months ago

Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

GlobeNewswire

9 months ago

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Zacks

10 months ago

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

10 months ago

Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Zacks

10 months ago

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

10 months ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

GlobeNewswire

10 months ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children

Clinical Trials Arena

10 months ago

Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children

MT Newswires

10 months ago

Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

GlobeNewswire

10 months ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago

Simply Wall St.

a year ago

Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

GlobeNewswire

a year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

GlobeNewswire

a year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

GlobeNewswire

a year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Zacks

a year ago

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma commences Phase II trial of luvelta for lung cancer

Clinical Trials Arena

a year ago

Sutro Biopharma commences Phase II trial of luvelta for lung cancer

MT Newswires

a year ago

Sutro Biopharma Initiates Phase 2 Trial of Luvelta in Non-Small Cell Lung Cancer

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

MT Newswires

a year ago

Truist Securities Adjusts Price Target on Sutro Biopharma to $15 From $18, Maintains Buy Rating

Companies Like Sutro Biopharma (NASDAQ:STRO) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Sutro Biopharma (NASDAQ:STRO) Are In A Position To Invest In Growth

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire

a year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

GlobeNewswire

a year ago

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

a year ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

a year ago

New Zealand scraps plan to tax livestock burps, farts

Business Wire

a year ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

a year ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

a year ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Simply Wall St.

a year ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable

Simply Wall St.

a year ago

Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable

Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks

MT Newswires

a year ago

Sutro Biopharma Q1 Loss Widens, Revenue Rises

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire

a year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for

The past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitable

Simply Wall St.

a year ago

The past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitable

MT Newswires

a year ago

BofA Securities Starts Sutro Biopharma With Buy Rating

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Zacks

a year ago

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

GlobeNewswire

a year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially

Simply Wall St.

a year ago

Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

GlobeNewswire

a year ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances

GuruFocus.com

a year ago

Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

Zacks

a year ago

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire

a year ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now

Zacks

a year ago

Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

Zacks

2 years ago

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

Sutro Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Gilat Awarded Multimillion-Dollar Defense Satellite Connectivity Project

GlobeNewswire

2 years ago

Gilat Awarded Multimillion-Dollar Defense Satellite Connectivity Project

Cipher Mining Announces Date of Fourth Quarter and Full Year 2023 Business Update Conference Call

GlobeNewswire

2 years ago

Cipher Mining Announces Date of Fourth Quarter and Full Year 2023 Business Update Conference Call

AM Best Withdraws Credit Ratings of Accelerant Re Ltd.

Business Wire

2 years ago

AM Best Withdraws Credit Ratings of Accelerant Re Ltd.

Apparel Retailer Stocks Q3 Recap: Benchmarking Victoria's Secret (NYSE:VSCO)

StockStory

2 years ago

Apparel Retailer Stocks Q3 Recap: Benchmarking Victoria's Secret (NYSE:VSCO)

European Parliament’s Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques

GlobeNewswire

2 years ago

European Parliament’s Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques

IBEX Limited to Announce Second Quarter 2024 Financial Results on February 8, 2024

GlobeNewswire

2 years ago

IBEX Limited to Announce Second Quarter 2024 Financial Results on February 8, 2024

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire

2 years ago

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Kicking Around Preliminary Earnings Trends in the Consumer Space

GuruFocus.com

2 years ago

Kicking Around Preliminary Earnings Trends in the Consumer Space

LINKBANCORP, Inc. (LNKB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

2 years ago

LINKBANCORP, Inc. (LNKB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Reuters

2 years ago

IN CASE YOU MISSED IT–Schedule of Reuters features from this week

Silvercorp Receives TSX Conditional Approval in Connection with OreCorp Offer

CNW Group

2 years ago

Silvercorp Receives TSX Conditional Approval in Connection with OreCorp Offer

Nestlé Joins Growing List of National and Multinational Companies Operating at the Tejon Ranch Commerce Center

GlobeNewswire

2 years ago

Nestlé Joins Growing List of National and Multinational Companies Operating at the Tejon Ranch Commerce Center

Turtle Beach (HEAR) Soars 11.9%: Is Further Upside Left in the Stock?

Zacks

2 years ago

Turtle Beach (HEAR) Soars 11.9%: Is Further Upside Left in the Stock?

Everlane CEO jumps to Designer Brands

Retail Dive

2 years ago

Everlane CEO jumps to Designer Brands

Unpacking Q3 Earnings: Tilly's (NYSE:TLYS) In The Context Of Other Apparel Retailer Stocks

StockStory

2 years ago

Unpacking Q3 Earnings: Tilly's (NYSE:TLYS) In The Context Of Other Apparel Retailer Stocks

Is GrafTech International Ltd. (NYSE:EAF) Potentially Undervalued?

Simply Wall St.

2 years ago

Is GrafTech International Ltd. (NYSE:EAF) Potentially Undervalued?

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

Simply Wall St.

2 years ago

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

Share on Social Networks: